Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 4
1(25.0%)
Phase 3
1(25.0%)
4Total
Phase 2(2)
Phase 4(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01088750Phase 4Completed

Surgery Alone or With CYC VBL and PRED or CVP Alone in Stage IA or IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Role: lead

NCT00416832Phase 2Completed

Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma

Role: lead

NCT00433459Phase 3Completed

Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma

Role: lead

NCT00398554Phase 2Completed

Combination Chemotherapy in Treating Young Male Patients With Hodgkin's Lymphoma

Role: lead

All 4 trials loaded